Search Results - "Van Den Eertwegh, A.J.M."

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101 by Grimm, M-O., Oya, M., Choueiri, T., Schmidinger, M., Quinn, D.I., Gravis-Mescam, G., Marseille, E., Van Den Eertwegh, A.J.M., Di Pietro, A., Mariani, M., Wang, J., Thomaidou, D., Albiges, L.

Get full text

4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes by Sluijter, B.J.R, van den Hout, M.F.C.M, Stam, A.G.M, Lougheed, S.M, Suhoski, M.M, van den Eertwegh, A.J.M, van den Tol, M.P, van Leeuwen, P.A.M, Meijer, S, Scheper, R.J, June, C.H, de Gruijl, T.D, Santegoets, S.J.A.M

“…Abstract We have been studying the re-activation of tumor-associated antigen (TAA)-specific CD8+ T cells in sentinel lymph nodes (SLN) of melanoma patients…”
Get full text

Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients by Baars, A., Claessen, A. M. E., van den Eertwegh, A. J. M., Gall, H. E., Stam, A. G. M., Meijer, S., Giaccone, G., Meijer, C. J. L. M., Scheper, R. J., Wagstaff, J., Vermorken, J. B., Pinedo, H. M.

“…Background Currently there is no standard adjuvant treatment following surgical resection of metastatic melanoma. We investigated whether surgery followed by…”
Get full text

MR-guided Stereotactic Body Radiation Therapy for Large Primary Kidney Tumors by Tetar, S.U., Bruynzeel, A., Oei, S.S., Senan, S., van der Wel, A.M., Slotman, B.J., van den Eertwegh, A.J.M., van Moorselaar, R.J.A., Lagerwaard, F.

Get full text

665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101 by Grimm, M-O., Oya, M., Choueiri, T.K., Schmidinger, M., Quinn, D.I., Gravis Mescam, G., Verzoni, E., Van den Eertwegh, A.J.M., di Pietro, A., Mariani, M., Wang, J., Thomaidou, D., Albiges, L.

Get full text

1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands by Breeschoten, J.V., Van den Eertwegh, A.J.M., de Wreede, L., Hilarius, D., van Zwet, E., Haanen, J.B.A.G., Blank, C.U., Aarts, M., Van den Berkmortel, F., de Groot, J.W.B., Hospers, G.A., Kapiteijn, E., Piersma, D., van Rijn, R.S., Stevense, M., Van der Veldt, A.A.M., Vreugdenhil, G., Boers-Sonderen, M., Suijkerbuijk, K., Wouters, M.W.J.M.

Get full text

1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality by De Meza, M.M., Ismail, R., Blokx, W.A.M., Blank, C.U., Van den Eertwegh, A.J.M., Aarts, M., van Akkooi, A.C.J., Van den Berkmortel, F., Boers-Sonderen, M., Kapiteijn, E., de Groot, J.W.B., Haanen, J.B.A.G., Hospers, G.A., Piersma, D., van Rijn, R.S., Van der Veldt, A.A.M., Vreugdenhil, G., Westgeest, H.M., Suijkerbuijk, K., Wouters, M.W.J.M.

Get full text

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry by Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Bloem, M., Blokx, W.A.M., Boers-Sonderen, M.J., Bonenkamp, J.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Haanen, J.B., Holtslag, C.E., Hospers, G.A.P., Piersma, D., van Rijn, R.S., Stevense-den Boer, A.M., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Vreugdenhil, G., Wouters, M.W.J.M., Portielje, J.E.A., de Glas, N.A.

“…Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of…”
Get full text

Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry by Kuppen, M.C.P., Westgeest, H.M., van den Eertwegh, A.J.M., Van Moorselaar, J., Mehra, N., Coenen, J.L., van Oort, I., van den Bergh, A.C.M., Lavalaye, J., Aben, K.K.H., Somford, D.M., de Wit, R., Bergman, A.M., Uyl-de Groot, C., Gerritsen, W.R.

Get full text

Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: Results from the Dutch CAPRI-registry by Notohardjo, J.C.L., Kuppen, M.C.P., Westgeest, H.M., van den Eertwegh, A.J.M., Van Moorselaar, J., Mehra, N., Coenen, J.L., van Oort, I., van den Bergh, A.C.M., Aben, K.K.H., Somford, D.M., de Wit, R., Bergman, A.M., Lavalaye, L., Uyl-de Groot, C., Gerritsen, W.R.

Get full text

865P - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: Results from the Dutch CAPRI-registry by Notohardjo, J.C.L., Kuppen, M.C.P., Westgeest, H.M., van den Eertwegh, A.J.M., Van Moorselaar, J., Mehra, N., Coenen, J.L., van Oort, I., van den Bergh, A.C.M., Aben, K.K.H., Somford, D.M., de Wit, R., Bergman, A.M., Lavalaye, L., Uyl-de Groot, C., Gerritsen, W.R.

“…Data on outcomes of a 3rd line life prolonging drug (LPD) in patients with metastatic castration resistant prostate cancer (mCRPC) is lacking. Aim of this…”
Get full text

869P - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry by Kuppen, M.C.P., Westgeest, H.M., van den Eertwegh, A.J.M., Van Moorselaar, J., Mehra, N., Coenen, J.L., van Oort, I., van den Bergh, A.C.M., Lavalaye, J., Aben, K.K.H., Somford, D.M., de Wit, R., Bergman, A.M., Uyl-de Groot, C., Gerritsen, W.R.

“…Radium-223 dichloride (Ra-223) is a targeted alpha-emitter that selectively binds to areas of increased bone turnover in bone metastases. In the ALSYMPCA trial…”
Get full text

37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis by Breeschoten, J.V., Wouters, M., Hilarius, D., Haanen, J.B.A.G., Blank, C.U., Aarts, M., Van den Berkmortel, F., de Groot, J.W., Hospers, G.A., Kapiteijn, E., Piersma, D., Van Rijn, R., Suijkerbuijk, K., Blokx, W.A.M., Tije, A. Ten, Van der Veldt, A.A.M., Vreugdenhil, G., Boers-Sonderen, M., van den Eertwegh, A.J.M.

Get full text

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry by van Zeijl, M.C.T., de Wreede, L.C., van den Eertwegh, A.J.M., Wouters, M.W.J.M., Jochems, A., Schouwenburg, M.G., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., ten Tije, A.J., van der Veldt, A.A.M., Vreugdenhil, G., van der Hoeven, J.J.M., Haanen, J.B.A.G.

“…The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time…”
Get full text

Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study by Boekhout, A.H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., Hospers, G.A., de Groot, J.W., Aarts, M.J.B., Kapiteijn, E., Ten Tije, A.J., Piersma, D., Vreugdenhil, G., Van der Veldt, A.A.M., Suijkerbuijk, K.P.M., Rozeman, E.A., Neyns, B., Janssen, K.J., van de Poll-Franse, L.V., Blank, C.U.

Get full text

Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands by van Zeijl, M.C.T., Wouters, M W J M, van den Eertwegh, A.J.M., de Wreede, L.C., Aarts, M.J.B., van Akkooi, A.C.J., Van den Berkmortel, F W P J, de Groot, J.W., Boers-Sonderen, M.J., van der Hoeven, J.J.M., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., Ten Tije, A.J., Van der Veldt, A.A.M., Vreugdenhil, G., Haanen, J B A G

Get full text

1353P - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands by van Zeijl, M.C.T., Wouters, M W J M, van den Eertwegh, A.J.M., de Wreede, L.C., Aarts, M.J.B., van Akkooi, A.C.J., Van den Berkmortel, F W P J, de Groot, J.W., Boers-Sonderen, M.J., van der Hoeven, J.J.M., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., Ten Tije, A.J., Van der Veldt, A.A.M., Vreugdenhil, G., Haanen, J B A G

“…In phase III trials, the results of ipilimumab plus nivolumab combination therapy (IPI+NIVO) are promising for metastatic melanoma (MM), despite many…”
Get full text

1621P - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study by Boekhout, A.H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., Hospers, G.A., de Groot, J.W., Aarts, M.J.B., Kapiteijn, E., Ten Tije, A.J., Piersma, D., Vreugdenhil, G., Van der Veldt, A.A.M., Suijkerbuijk, K.P.M., Rozeman, E.A., Neyns, B., Janssen, K.J., van de Poll-Franse, L.V., Blank, C.U.

“…Since the introduction of immune-checkpoint blockade, the overall survival has significantly improved for patients with advanced melanoma. However, to date,…”
Get full text

EP-1356: SBRT benefit in oligometastatic prostate cancer patients detected by [18 F]fluoromethylcholine PET/CT by Bouman-Wammes, E., Van Dodewaard-de Jong, J.M., Dahele, M., Cysouw, M.C.F., Hoekstra, O.S., Piet, A.H.M., Van den Eertwegh, A.J.M., Verheul, H.M.W., Oprea-Lager, D.E., V.M.H

Get full text

P108 Real-world use of PSMA PET/CT in metastatic hormone-sensitive prostate cancer: results from the CAPRI-3 Registry by van der Velden, K.J.M., Bosch, D., Bergman, A.M., Van Den Bergh, F., Van Der Doelen, M.J., Van Den Eertwegh, A.J.M., Lavalaye, J., Van Moorselaar, R.J.A., Somford, D.M., Tascilar, M., Korn, M., Vassilev, Z., Raval, A., Van Der Winkel, A., Pisa, F., Uyl - De Groot, C.A., Kuppen, M.C.P., Van Oort, I.M.

Get full text